Histone methyltransferase KMT5A gene modulates oncogenesis and lipid metabolism of papillary thyroid cancer in vitro

Liao,Tian; Wang,Yuan-Jin; Hu,Jia-Qian; Wang,Yu; Han,Li-Tao; Ma,Ben; Shi,Rong-Liang; Qu,Ning; Wei,Wen-Jun; Guan,Qing; Xiang,Jun; Chen,Jia-Ying; Sun,Guo-Hua; Li,Duan-Shu; Mu,Xiang-Ming; Ji,Qing-Hai

doi:10.3892/or.2018.6295

Histone methyltransferase KMT5A gene modulates oncogenesis and lipid metabolism of papillary thyroid cancer in vitro

Authors:
- Tian Liao
- Yuan-Jin Wang
- Jia-Qian Hu
- Yu Wang
- Li-Tao Han
- Ben Ma
- Rong-Liang Shi
- Ning Qu
- Wen-Jun Wei
- Qing Guan
- Jun Xiang
- Jia-Ying Chen
- Guo-Hua Sun
- Duan-Shu Li
- Xiang-Ming Mu
- Qing-Hai Ji
View Affiliations

Affiliations: Department of Head and Neck Surgery, Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China, Department of General Surgery, Yancheng First People's Hospital, The Fourth Affiliated Hospital of Nantong Medical College, Yancheng, Jiangsu 224000, P.R. China
Published online on: March 5, 2018 https://doi.org/10.3892/or.2018.6295
Pages: 2185-2192

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

KMT5A (known as PR-Set7/9, SETD8 and SET8), a member of the SET domain containing methyltransferase family specifically targeting H4K20 for methylation, has been implicated in multiple biological processes. In the present study, we identified that KMT5A was elevated in 50 pairs of papillary thyroid cancer tissue samples and in cell lines K1 and TPC-1 by qRT-PCR and western blotting, as well as by immunohistochemical staining. CCK-8 assay and flow cytometric analysis revealed that inhibition of KMT5A attenuated proliferation and induced apoptosis. Transwell assays revealed that cell migration and invasion were suppressed in KMT5A-knockdown cells. Moreover, the inhibition of KMT5A arrested the cell cycle in the G1/S phase of papillary thyroid cancer cells. The TCGA data revealed that elevated KMT5A expression was significantly correlated with extrathyroidal extension, lymph node metastasis and advanced pathological stage of papillary thyroid cancer. Furthermore, we observed that inhibition of KMT5A suppressed the expression of SREBP1, SCD, FASN and ACC, key molecules involved in lipid metabolism and decreased the level of malondialdehyde in papillary thyroid cancer cells. In conclusion, KMT5A may be a novel oncogenic factor, specifically a regulator for lipid metabolism in papillary thyroid carcinoma.

View Figures

View References

1	Morris LG, Tuttle RM and Davies L: Changing trends in the incidence of thyroid cancer in the United States. JAMA Otolaryngol Head Neck Surg. 142:709–711. 2016. View Article : Google Scholar : PubMed/NCBI
2	Xing M, Alzahrani AS, Carson KA, Shong YK, Kim TY, Viola D, Elisei R, Bendlová B, Yip L, Mian C, et al: Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol. 33:42–50. 2015. View Article : Google Scholar : PubMed/NCBI
3	Carracedo A, Cantley LC and Pandolfi PP: Cancer metabolism: Fatty acid oxidation in the limelight. Nat Rev Cancer. 13:227–232. 2013. View Article : Google Scholar : PubMed/NCBI
4	Santos CR and Schulze A: Lipid metabolism in cancer. FEBS J. 279:2610–2623. 2012. View Article : Google Scholar : PubMed/NCBI
5	Baenke F, Peck B, Miess H and Schulze A: Hooked on fat: The role of lipid synthesis in cancer metabolism and tumour development. Dis Model Mech. 6:1353–1363. 2013. View Article : Google Scholar : PubMed/NCBI
6	von Roemeling CA, Marlow LA, Pinkerton AB, Crist A, Miller J, Tun HW, Smallridge RC and Copland JA: Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals stearoyl CoA desaturase 1 as a novel therapeutic target. J Clin Endocrinol Metab. 100:E697–E709. 2015. View Article : Google Scholar : PubMed/NCBI
7	Uddin S, Siraj AK, Al-Rasheed M, Ahmed M, Bu R, Myers JN, Al-Nuaim A, Al-Sobhi S, Al-Dayel F, Bavi P, et al: Fatty acid synthase and AKT pathway signaling in a subset of papillary thyroid cancers. J Clin Endocrinol Metab. 93:4088–4097. 2008. View Article : Google Scholar : PubMed/NCBI
8	Li Z, Nie F, Wang S and Li L: Histone H4 Lys 20 monomethylation by histone methylase SET8 mediates Wnt target gene activation. Proc Natl Acad Sci USA. 108:3116–3123. 2011. View Article : Google Scholar : PubMed/NCBI
9	Abbas T, Shibata E, Park J, Jha S, Karnani N and Dutta A: CRL4^Cdt2 regulates cell proliferation and histone gene expression by targeting PR-Set7/Set8 for degradation. Mol Cell. 40:9–21. 2010. View Article : Google Scholar : PubMed/NCBI
10	Centore RC, Havens CG, Manning AL, Li JM, Flynn RL, Tse A, Jin J, Dyson NJ, Walter JC and Zou L: CRL4^Cdt2-mediated destruction of the histone methyltransferase Set8 prevents premature chromatin compaction in S phase. Mol Cell. 40:22–33. 2010. View Article : Google Scholar : PubMed/NCBI
11	Houston SI, McManus KJ, Adams MM, Sims JK, Carpenter PB, Hendzel MJ and Rice JC: Catalytic function of the PR-Set7 histone H4 lysine 20 monomethyltransferase is essential for mitotic entry and genomic stability. J Biol Chem. 283:19478–19488. 2008. View Article : Google Scholar : PubMed/NCBI
12	Oda H, Hübner MR, Beck DB, Vermeulen M, Hurwitz J, Spector DL and Reinberg D: Regulation of the histone H4 monomethylase PR-Set7 by CRL4^Cdt2-mediated PCNA-dependent degradation during DNA damage. Mol Cell. 40:364–376. 2010. View Article : Google Scholar : PubMed/NCBI
13	Wu S, Wang W, Kong X, Congdon LM, Yokomori K, Kirschner MW and Rice JC: Dynamic regulation of the PR-Set7 histone methyltransferase is required for normal cell cycle progression. Genes Dev. 24:2531–2542. 2010. View Article : Google Scholar : PubMed/NCBI
14	Shi X, Kachirskaia I, Yamaguchi H, West LE, Wen H, Wang EW, Dutta S, Appella E and Gozani O: Modulation of p53 function by SET8-mediated methylation at lysine 382. Mol Cell. 27:636–646. 2007. View Article : Google Scholar : PubMed/NCBI
15	Yang F, Sun L, Li Q, Han X, Lei L, Zhang H and Shang Y: SET8 promotes epithelial-mesenchymal transition and confers TWIST dual transcriptional activities. EMBO J. 31:110–123. 2012. View Article : Google Scholar : PubMed/NCBI
16	Liao T, Wen D, Ma B, Hu JQ, Qu N, Shi RL, Liu L, Guan Q, Li DS and Ji QH: Yes-associated protein 1 promotes papillary thyroid cancer cell proliferation by activating the ERK/MAPK signaling pathway. Oncotarget. 8:11719–11728. 2017. View Article : Google Scholar : PubMed/NCBI
17	Wang Z, Dai X, Zhong J, Inuzuka H, Wan L, Li X, Wang L, Ye X, Sun L, Gao D, et al: SCF^β−TRCP promotes cell growth by targeting PR-Set7/Set8 for degradation. Nat Commun. 6:101852015. View Article : Google Scholar : PubMed/NCBI
18	Swain JF, Dinler G, Sivendran R, Montgomery DL, Stotz M and Gierasch LM: Hsp70 chaperone ligands control domain association via an allosteric mechanism mediated by the interdomain linker. Mol Cell. 26:27–39. 2007. View Article : Google Scholar : PubMed/NCBI
19	Cook KL, Soto-Pantoja DR, Clarke PA, Cruz MI, Zwart A, Wärri A, Hilakivi-Clarke L, Roberts DD and Clarke R: Endoplasmic reticulum stress protein GRP78 modulates lipid metabolism to control drug sensitivity and antitumor immunity in breast cancer. Cancer Res. 76:5657–5670. 2016. View Article : Google Scholar : PubMed/NCBI
20	Sorrentino G, Ruggeri N, Specchia V, Cordenonsi M, Mano M, Dupont S, Manfrin A, Ingallina E, Sommaggio R, Piazza S, et al: Metabolic control of YAP and TAZ by the mevalonate pathway. Nat Cell Biol. 16:357–366. 2014. View Article : Google Scholar : PubMed/NCBI
21	Freed-Pastor WA, Mizuno H, Zhao X, Langerød A, Moon SH, Rodriguez-Barrueco R, Barsotti A, Chicas A, Li W, Polotskaia A, et al: Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell. 148:244–258. 2012. View Article : Google Scholar : PubMed/NCBI
22	Li X, Wu JB, Chung LW and Huang WC: Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations. Oncotarget. 6:41018–41032. 2015. View Article : Google Scholar : PubMed/NCBI
23	Horton JD, Goldstein JL and Brown MS: SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 109:1125–1131. 2002. View Article : Google Scholar : PubMed/NCBI
24	Dulev S, Tkach J, Lin S and Batada NN: SET8 methyltransferase activity during the DNA double-strand break response is required for recruitment of 53BP1. EMBO Rep. 15:1163–1174. 2014. View Article : Google Scholar : PubMed/NCBI
25	Liu B, Zhang X, Song F, Liu Q, Dai H, Zheng H, Cui P, Zhang L, Zhang W and Chen K: A functional single nucleotide polymorphism of SET8 is prognostic for breast cancer. Oncotarget. 7:34277–34287. 2016.PubMed/NCBI
26	Hou L, Li Q, Yu Y, Li M and Zhang D: SET8 induces epithelial mesenchymal transition and enhances prostate cancer cell metastasis by cooperating with ZEB1. Mol Med Rep. 13:1681–1688. 2016. View Article : Google Scholar : PubMed/NCBI
27	Shi XL, Guo ZJ, Wang XL, Liu XL and Shi GF: SET8 expression is associated with overall survival in gastric cancer. Genet Mol Res. 14:15609–15615. 2015. View Article : Google Scholar : PubMed/NCBI
28	Aylon Y and Oren M: The Hippo pathway, p53 and cholesterol. Cell Cycle. 15:2248–2255. 2016. View Article : Google Scholar : PubMed/NCBI